The invention relates to the field of recombinant antibodies for use in humancancer therapy. More specifically the invention provides compositions or mixturesof antibodies capable of binding human EGFR. Antibody compositions with 3 ormore antibodies have shown synergy in reduction of proliferation of representativecancer cell lines. Advantageous results have also been obtained with a compositioncomprising two different chimeric anti-hEGFR antibodies which show a new mechanismof action based on rapid and efficient receptor internalisation, inductionof terminal differentiation and subsequent tumour eradication in an animalmodel. The antibodies of the invention can be manufactured in one bioreactoras a polyclonal antibody.
